MediWound MDWD 深 沪
等待开盘 12-20 09:30:00 美东时间
18.91
+0.070
+0.37%
华盛通- 最 高18.99
- 今 开18.91
- 成交量 2.39万股
- 最 低 18.6603
- 昨 收 18.84
- 总市值 2.06亿
- 52周最高 22.505
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.14
- 委 比 36.05%
- 总股本 1087.56万
- 历史最高 135.17
- 量 比 0.70
- 振 幅 1.75%
- 历史最低 7.10
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MediWound Announces Peer-Reviewed Publication Of New Prospective Clinical Data Showing NexoBrid Substantially Reduces Embedded Particles Associated With Traumatic Tattoos Following Abrasion And Blast Injuries
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast InjuriesProspective clinical data show NexoBrid® removes embedded particles
12-10 20:13
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $36
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and raises the price target from $31 to $36.
11-21 19:16
MediWound’s Q3 2025: Growth and Strategic Advances
Mediwound ( ($MDWD) ) has released its Q3 earnings. Here is a breakdown of the ...
11-21 11:58
MediWound Q3 EPS $(0.24) Beats $(0.81) Estimate, Sales $5.429M Miss $6.646M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.81) by 70.44 percent. This is a 75.51 percent increase over losses of $(0.98) per share from the
11-20 20:02
Earnings Scheduled For November 20, 2025
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is likely to report qu...
11-20 19:11
Examining the Future: MediWound's Earnings Outlook
MediWound (NASDAQ:MDWD) will release its quarterly earnings report on Thursday,...
11-20 00:03
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET. A webcast will be available on the company's Investor Relations website. Vericel, a leader in advanced therapies for sports medicine and severe burn care, markets three products: MACI, Epicel, and NexoBrid. For more information, visit www.vcel.com or contact investor relations at ir@vcel.com or +1 (734) 418-...
11-14 13:30
MediWound to Report Third Quarter 2025 Financial Results
MediWound Ltd. will release its Q3 2025 financial results on November 20, 2025, followed by a conference call and webcast at 8:30 a.m. ET. Dial-in details and a webcast link are provided. The company, a leader in enzymatic therapeutics for tissue repair, markets NexoBrid® for burn treatment and is advancing EscharEx® for chronic wounds. More info on its website or via contacts listed.
11-05 12:30
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
MediWound Ltd. announced the successful completion of commissioning its expanded GMP manufacturing facility in Yavne, Israel, which will increase production capacity for NexoBrid by sixfold ahead of full operational readiness by year-end 2025. NexoBrid, a topically administered biological orphan drug for enzymatic removal of eschar in thermal burns, is approved in over 40 countries. This milestone reflects MediWound's commitment to meeting global...
11-03 13:00
